Graeme McRobbie
Associate Director Formulation Science Radiopharmaceuticals Bicycle Therapeutics plc
Graeme McRobbie holds a PhD in Medicinal Chemistry from the University of Hull and has over 17 years of experience as a CMC radiopharmaceutical scientist working in nuclear medicine. He began his career at GE Healthcare and is currently an Associate Director of Formulation Science at Bicycle Therapeutics.
He specializes in the design and development of radiopharmaceutical drug products and their manufacturing processes. His expertise spans the entire product lifecycle, from research and innovation through to early-stage clinical studies and commercial readiness.
Seminars
Tuesday 1st December 2026
Automation Strategy Lab: Which Radiopharmaceutical Manufacturing Platform Is Right for Your Programme?
1:30 pm
- Evaluate the latest radiopharmaceutical automation platforms to make informed manufacturing decisions that support scalable clinical and commercial development.
- Comparing the strengths, limitations and practical considerations of different radiopharmaceutical automation platforms, including cassette-based and modular manufacturing systems
- Debating how developers should evaluate automation hardware, reagent availability, operational flexibility and scalability when selecting a manufacturing platform
- Exploring how automation decisions made during early development can impact tech transfer, clinical supply strategy and future commercial readiness
Wednesday 2nd December 2026
Building Global Radiopharmaceutical Manufacturing Networks: From Process Development to Clinical Supply Readiness
12:00 pm
- Exploring the key considerations when designing radiopharmaceutical manufacturing processes capable of supporting global clinical development programmes
- Sharing lessons learned from selecting CDMOs, establishing tech transfer strategies and preparing manufacturing networks for multi-site clinical trials
- Examining how process development, formulation strategy and operational planning must evolve when transitioning from imaging agents to therapeutic radiopharmaceuticals
